References
Ozaki S, Harada T, Fujii S, Nakamura S, Miki H, Nakano A, et al. Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma. Int J Hematol. 2011;93:257–9.
Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, et al. Immunomodulatory drug CC5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063–7.
Zangari M, Elice F, Tricot G. Immunomodulatory drugs in multiple myeloma. Expert Opin Investig Drugs. 2005;14:1411–8.
Quach H, Ritchie D, Stewart AK, Neason P, Harrison S, Smyth MJ, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24:22–32.
Dredge K, Marriott JB, Macdonald CD. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer. 2002;87:1166–72.
Conflict of interest
Drs. Matsumura I and Morita Y received a grant for research from Celgene Corporation. All other authors declare no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Morita, Y., Shimada, T., Yamaguchi, T. et al. Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide. Int J Hematol 94, 583–584 (2011). https://doi.org/10.1007/s12185-011-0973-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-011-0973-x